Alithea Bio

PUBLIC

Company	Alithea Bio
Tagline	HLA immunopeptidomics platform for cancer immunotherapy
Headquarters	Freiburg, Germany
Founded	2019
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)

Links

PUBLIC

• Website: https://alithea-bio.com/
• LinkedIn: https://www.linkedin.com/company/alithea-bio

Executive Summary

PUBLIC Alithea Bio is building a computational platform to identify the specific protein fragments, or peptides, that a patient's immune system can recognize as foreign, a foundational step for developing personalized cancer immunotherapies. The company's focus on HLA immunopeptidomics positions it at the intersection of mass spectrometry proteomics and bioinformatics, aiming to solve a critical bottleneck in neoantigen discovery and T-cell therapy safety [Alithea Bio]. Founded in 2019, the company has operated in a relatively quiet, research-focused mode from its base in Freiburg, Germany, participating in regional accelerator programs like BadenCampus and securing non-dilutive support from the Women TechEU initiative and a German Mittelstand innovation grant [LinkedIn - Fanny Giannou], [PMWC].

Its core offering, the HLA-Compass software suite, is designed to characterize peptides presented by HLA molecules and predict off-target toxicities, a key risk in cell therapies [Alithea Bio]. The platform's claimed differentiation rests on a proprietary database built from thousands of samples, which the company says enables more accurate ligand identification and quantification [PMWC]. The founding team combines scientific and commercial backgrounds: Tim Fugmann, the Chief Scientific Officer, brings a technical foundation from ETH Zürich and experience in HLA peptidomics applications, while CEO Fanny Giannou contributes a business development background from the energy sector and is pursuing an executive MBA [Crunchbase], [LinkedIn - Tim Fugmann].

Public capitalization details are absent; no named investors or funding rounds have been disclosed, suggesting the company has been bootstrapped or funded through grants and early commercial contracts, which it claims to have completed [Alithea Bio about-us]. For investors, the next 12-18 months will be defined by the company's ability to transition from platform development and initial contracts to securing named pharmaceutical partnerships, publishing validation data in peer-reviewed journals, and likely pursuing its first institutional funding round to scale commercial and research operations. Data Accuracy: YELLOW -- Core product claims and team roles are from the company's website and LinkedIn profiles; accelerator participation is corroborated. No independent verification of commercial contracts, database scale, or funding.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)

Company Overview

PUBLIC

Alithea Bio operates as a biotechnology company, formally Alithea Biotechnology GmbH, headquartered in Freiburg, Germany. The company was founded in 2019, positioning itself in the precision immunotherapy space with a focus on HLA immunopeptidomics [Crunchbase]. Its public narrative centers on advancing T-cell mediated cancer treatments by characterizing the peptides presented by the immune system's HLA molecules [Alithea Bio].

The founding team includes Fanny Giannou, listed as founder and CEO, and Tim Fugmann, identified as Chief Scientific Officer and co-founder [Crunchbase, Bruker]. Giannou's background includes business development roles outside biotech, while Fugmann's profile indicates scientific training at ETH Zürich and expertise in HLA peptidomics applications [Crunchbase, LinkedIn - Tim Fugmann]. The company has participated in several European support programs, including the BadenCampus accelerator, the Zentrales Innovationsprogramm Mittelstand (ZIM), and the Women TechEU award in 2024 [LinkedIn - Fanny Giannou]. A key operational milestone, claimed on the company website, is the completion of its first commercial contracts, though specific customers and deal sizes are not disclosed [Alithea Bio].

Data Accuracy: YELLOW -- Founding year and entity name corroborated by Crunchbase; team roles and accelerator participation cited from LinkedIn and company materials. Key milestone (first contracts) is a company-only claim.

Product and Technology

MIXED

Alithea Bio's commercial offering centers on a software platform for analyzing HLA-presented peptides, a critical dataset for designing cancer immunotherapies. The company's website positions its core product, HLA-Compass, as a bioinformatics pipeline for characterizing these peptides, with stringent quality control and the ability to map peptides to specific HLA alleles [Alithea Bio]. A companion tool, NeoZOOM, is listed for predicting off-target toxicity, a major safety concern in cell therapy development [Alithea Bio]. The underlying technology stack appears to integrate immunopeptidomics, proteogenomics, and applied AI, though the specific algorithms and software architecture are not detailed in public materials [Alithea Bio].

The platform's differentiation is anchored in a proprietary dataset. According to a speaker bio for co-founder Tim Fugmann, the company has compiled an HLA peptide database from 3,000 samples, covering 1.1 million ligands with abundance data across health and disease states [PMWC]. This resource is intended to provide the training data and reference material needed to improve neoantigen discovery and safety profiling. The company also claims a validated proteogenomics pipeline for neoantigen discovery from patient tumor samples, which integrates genomic and proteomic data [Alithea Bio].

Public traction for the product suite is limited to a company statement. The 'About Us' page notes that first commercial contracts have been completed, but no customer names, contract values, or deployment timelines are provided [Alithea Bio about-us]. The website includes a client login portal for HLA-Compass, suggesting an active, albeit undisclosed, user base [Alithea Bio].

Data Accuracy: YELLOW -- Product claims are sourced from the company website; the database size is cited in a third-party speaker bio but not independently verified. Commercial contract claims are company-only.

Market Research

PUBLIC The commercial momentum for neoantigen discovery platforms is driven by a convergence of clinical validation, increasing immunotherapy adoption, and a persistent need to improve therapeutic safety profiles.

Third-party market sizing for the specific niche of HLA immunopeptidomics is not publicly available in the cited sources. However, the company's target applications sit within larger, well-defined markets. The global neoantigen discovery platform market was valued at approximately $1.2 billion in 2023, with projections to reach $3.5 billion by 2030, according to a Grand View Research report [Grand View Research, 2023]. The broader cancer immunotherapy market, which serves as the ultimate end-market for these tools, is significantly larger, with Precedence Research estimating it at $116 billion in 2023 and growing at a compound annual rate of 9.5% [Precedence Research, 2024]. These figures provide an analogous context for the potential scale of the tools and services Alithea Bio is developing.

Key demand drivers for this segment include the clinical and commercial success of T-cell engaging therapies, such as CAR-T and TCR-T therapies, which have validated the approach of targeting specific tumor antigens. This success has spurred investment in next-generation modalities, including personalized cancer vaccines, which rely heavily on accurate neoantigen identification. A secondary, and perhaps more immediate, driver is the growing regulatory and commercial focus on mitigating off-target toxicities in cell therapies, a problem Alithea Bio's NeoZOOM tool explicitly addresses [Alithea Bio website]. The expansion of biomarker-driven clinical trials and the integration of multi-omics data in oncology R&D further create a receptive environment for specialized bioinformatics platforms.

Adjacent and substitute markets influence the opportunity. Direct substitutes include other computational neoantigen prediction tools that rely solely on genomic sequencing data, which are less expensive but may have lower predictive accuracy for HLA presentation. Adjacent markets include the broader proteomics and mass spectrometry services sector, as well as contract research organizations (CROs) offering immunology and biomarker discovery services. The company's stated wedge into pharma R&D via target validation and safety profiling suggests it is initially competing for budget within early-stage therapeutic discovery programs, rather than the later-stage clinical diagnostics market.

Regulatory and macro forces are largely favorable but carry nuance. The regulatory pathway for companion diagnostics and clinical decision support software is complex and varies by region, which could affect the long-term productization of any platform. However, the current focus on research-use-only tools sidesteps immediate regulatory hurdles. Macro trends, including increased venture funding in European biotech and public initiatives like the EU's Cancer Mission, provide a supportive funding and policy environment for oncology innovation. The company's participation in programs like Women TechEU and ZIM indicates an ability to access non-dilutive public grants, which is a common early-stage strategy in European life sciences.

Neoantigen Discovery Platforms (2023) | 1200 | $M
Cancer Immunotherapy Market (2023) | 116000 | $M

The available market data illustrates the layered opportunity: Alithea Bio's tools address a specialized, high-growth niche within a massive and expanding therapeutic end-market. The immediate served market is a fraction of the broader immunotherapy spend, focused on R&D tooling budgets.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous segments; specific immunopeptidomics platform TAM is not confirmed.

Competitive Landscape

MIXED Alithea Bio operates in a specialized niche where the primary competition is not from direct, named platform peers, but from established research tools, internal pharma R&D, and adjacent service providers.

No named direct competitors were surfaced in the available research. The competitive analysis is therefore based on the broader ecosystem of alternatives a biopharma client would consider when sourcing HLA peptidomics capabilities.

• Internal R&D teams. Large pharmaceutical companies with dedicated immunology and bioinformatics divisions represent the most significant competitive force. These teams can develop proprietary pipelines in-house, though they may lack the specialized focus and curated dataset Alithea claims to offer [Alithea Bio website].
• Mass spectrometry and proteomics CROs. Contract research organizations offering general proteomics services provide a substitute. While they possess the core instrumentation (e.g., Bruker timsTOF systems), they may not offer the same end-to-end, AI-driven bioinformatics pipeline for HLA-specific peptide characterization and safety profiling that Alithea markets [Bruker webinar].
• Bioinformatics software vendors. Companies selling standalone software for peptide binding prediction or neoantigen ranking compete on a component basis. Alithea’s integrated platform approach, combining wet-lab services with its HLA-Compass software, aims to bundle these steps.
• Academic consortia and public databases. Resources like the Immune Epitope Database (IEDB) provide foundational, publicly available data. Alithea’s proposed edge rests on a larger, proprietary database of quantified HLA ligands from clinical samples, which it claims covers 1.1 million ligands from 3000 samples [PMWC].

The company’s most defensible edge, as presented, is its claimed proprietary HLA peptide database. If the dataset of 1.1 million ligands with relative abundance data is indeed exclusive and clinically validated, it creates a data moat that is expensive and time-consuming for a new entrant to replicate. This edge is perishable, however, if larger competitors or consortia generate similar or larger datasets, or if the data’s utility in predicting clinical outcomes is not demonstrated. A second potential edge is the integrated offering of wet-lab services (peptide purification) with proprietary bioinformatics, reducing client friction compared to assembling a workflow from multiple vendors.

The exposure is significant. The company lacks the brand recognition, commercial track record, and capital reserves of established CROs. Its platform is unproven at scale, with no publicly disclosed pharmaceutical partnerships or peer-reviewed validation of its tools’ predictive power. A key vulnerability is the "componentization" of its offering; a large pharma partner could license the core software idea and rebuild it internally, or a well-funded proteomics CRO could decide to build a competing HLA-specialized division.

The most plausible 18-month scenario is one of validation or obscurity. If Alithea Bio can convert its first commercial contracts into a published case study with a reputable biotech partner, it could establish credibility and attract a Series A round to scale commercial efforts. The "winner" in this niche will likely be the first to secure a multi-year, platform-level partnership with a top-20 pharma company for TCR therapy development. Conversely, the "loser" will be any player that remains in the service-for-hire model without generating proprietary, patentable insights or therapeutic candidates. Without visible commercial traction or funding, Alithea risks being outmaneuvered by better-capitalized entrants who recognize the same market wedge.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated market position and broader industry structure; no direct competitor names are publicly cited.

Opportunity

PUBLIC

If Alithea Bio's platform can reliably map the immunopeptidome to de-risk and accelerate the development of cell therapies and cancer vaccines, it could become a foundational data and analytics layer for a multi-billion dollar precision immunotherapy market.

The headline opportunity is to establish the company as the default bioinformatics and data partner for target validation in T-cell receptor (TCR)-based therapies. This outcome is reachable because the core technical challenge,accurately predicting which tumor-specific peptides are presented by HLA molecules and which might cause dangerous off-target effects,remains a primary bottleneck in the field [Alithea Bio]. Alithea's stated wedge is not a new therapeutic molecule, but a service and software platform to improve the safety and efficacy profiles of other companies' candidates. By positioning its HLA-Compass and NeoZOOM tools as essential for Investigational New Drug (IND) application packages, the company could embed itself into the R&D workflows of dozens of biotech firms, becoming a category-defining infrastructure provider akin to a specialized CRO for immunopeptidomics.

Growth could follow several distinct, concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
The Data Moat	Alithea's proprietary HLA peptide database becomes the industry reference, licensed broadly for target discovery.	Publication of a landmark paper validating the database's predictive power for neoantigen immunogenicity.	The company claims a database built from 3000 samples covering 1.1 million ligands [PMWC]. This scale, if validated, creates a significant early-mover data asset.
The Regulatory Wedge	NeoZOOM for off-target toxicity prediction becomes a de facto standard for TCR therapy safety packages submitted to agencies like the FDA and EMA.	A high-profile partnership with a late-stage biotech that publicly credits Alithea's tools for a successful regulatory submission.	The platform's explicit focus on "off-target safety profiling" directly addresses a critical regulatory hurdle for cell therapies [Alithea Bio].
The Platform Pivot	The company transitions from project-based services to a scalable SaaS model, selling software subscriptions for its HLA-Compass analysis suite.	The launch of a self-service, cloud-based version of HLA-Compass with tiered pricing for academic and biotech users.	The existence of a "HLA-Compass Login" portal and mention of "Release Notes" suggests an evolving software product, not just a service [Alithea Bio].

Compounding for Alithea would look like a classic data network effect in a specialized domain. Each new client project analyzing patient or cell-line samples would feed new, rare HLA-peptide data back into the proprietary database. This expanding dataset would improve the accuracy of the company's AI-driven binding and toxicity prediction models, making the platform more valuable for the next client. Early evidence of this flywheel is the claim of "first commercial contracts completed" [Alithea Bio], which, while unverified, suggests the initial process of converting expertise into paid data generation has begun. The more the platform is used, the wider the gap becomes between its empirically trained models and those built on public datasets alone.

The size of the win, should the Data Moat or Regulatory Wedge scenario play out, can be framed by looking at comparable companies that provide essential R&D tools to the biopharma industry. Public peers like Recursion Pharmaceuticals (NASDAQ: RXRX), which operates a platform for drug discovery, or gene synthesis leader Twist Bioscience (NASDAQ: TWST), trade at enterprise values reflecting the high-margin, recurring nature of selling innovation tools. A more direct, though private, comparable might be a platform CRO like Evotec SE, which has a market capitalization in the billions of euros. If Alithea Bio captured even a single-digit percentage of the global spend on oncology preclinical R&D services,a market measured in the tens of billions annually,it could support a valuation in the hundreds of millions of dollars (scenario, not a forecast). The prize is not in selling a single blockbuster drug, but in taking a small, high-value cut from the development of many of them.

Data Accuracy: YELLOW -- Opportunity framing is extrapolated from company-stated mission and product claims; database scale claim is from a speaker bio but not independently verified. Growth scenarios are plausible but not yet evidenced by public partnerships or commercial traction.

Sources

PUBLIC

1. [Alithea Bio] Alithea bio | https://alithea-bio.com/

2. [Alithea Bio] About Us - Alithea Biotechnology GmbH | https://alithea-bio.com/about-us/

3. [Crunchbase] Alithea Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/alithea-bio

4. [LinkedIn - Fanny Giannou] Fanny Giannou - Berlin, Berlin, Germany | Professional Profile | LinkedIn | https://www.linkedin.com/in/fanny-giannou-352416225/

5. [PMWC] Tim Fugmann - 2023sv - PMWC Precision Medicine World Conference | https://www.pmwcintl.com/speaker/tim-fugmann-478_alithea-bio-ug_2023sv

6. [Bruker] Unlocking the full potential of immunopeptidomics with the timsTOF Ultra | Bruker | https://www.bruker.com/en/news-and-events/webinars/2024/unlocking-the-full-potential-of-immunopeptidomics-with-the-timstof-ultra.html

7. [LinkedIn - Tim Fugmann] Tim Fugmann - Alithea Bio UG | LinkedIn | https://www.linkedin.com/in/tim-fugmann-a1639914/

8. [Grand View Research, 2023] Neoantigen Discovery Platform Market Size, Share & Trends Analysis Report | Grand View Research | https://www.grandviewresearch.com/industry-analysis/neoantigen-discovery-platform-market-report

9. [Precedence Research, 2024] Cancer Immunotherapy Market Size, Growth, Trends | Precedence Research | https://www.precedenceresearch.com/cancer-immunotherapy-market